Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101

Century Therapeutics, Inc.

2024-Q2 EPS reported -$0.82 revenue$1,625,000

Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.
Presented interim ELiPSE-1 trial data at ASCO showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas; dose escalation completed, dose expansion expected in 2H 2024.
Ended Q2 2024 with $269.6 million cash, equivalents, and investments; cash runway into 2026. GAAP operating expense guidance $150-$160 million.
Completed $60 million private placement and acquired Clade Therapeutics in April 2024, enhancing Allo-Evasion platform and adding preclinical αβ iT programs.
R&D expenses $27.2 million for Q2 2024 vs $22.7 million prior year; net loss $31.2 million vs $33.3 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.